Hot Stocks

The stock market changes from minute to minute, and what’s hot today may not be hot tomorrow. Our expert analysts spot hot stocks that are heating up before the crowd swoops in to bid prices higher, and our journalists sift through the noise to shine a light on trending investments -- in spaces ranging from quantum computing to marijuana stocks -- to determine whether they’re actually worth your time.

MicroVision Stock Looks Like a Tougher Proposition After 17X Move

By Josh Enomoto, InvestorPlace Contributor
In late 2016, I suggested that MVIS stock could be a huge winner. It’s made more than good on that potential which is part of its problem today.

Target Stock Is Slowing; The Company, Not So Much

By Dana Blankenhorn, InvestorPlace Contributor
Target's market cap is now equal to its sales, which is a danger sign. The TGT stock dividend is now yielding under 1.5%, another danger sign.

MoneyLine Podcast: 10 Stocks for the Grand Re-Opening

By InvestorPlace Research Staff
In today's episode of MoneyLine, Matt McCall reveals healthcare-related picks for the "grand re-opening" opportunity. See why he says this will be one of the best chances to make big money in the next two years.

Hyliion Stock Still Has What It Takes to Shift Into Overdrive

By InvestorPlace Research Staff
Other EV stocks have garnered much more attention by investors, but HYLN stock could wind up being a quiet winner in this space.

ChargePoint Has a Super-Charged Future That’s Not Here Yet

By Chris Markoch, InvestorPlace Contributor
ChargePoint is likely to provide an ample EV charging network. But for ChargePoint stock to grow, it needs EV demand to do the same.

Bionano Genomics Would Have Been a Great Find Months Ago

By Alex Sirois, InvestorPlace Contributor
BNGO stock shot up massively in the past few months. Now isn't the time to invest as the company must first prove its technology sells.

Gevo Is on the Right Track But Shares Are Overvalued

By Alex Sirois, InvestorPlace Contributor
GEVO stock is headed in the right direction in a sector with growth ahead. That said, investors should tread carefully now.

GME Stock Rises to $130. Time to Double Down or Take Profits?

By Thomas Yeung, CFA, InvestorPlace Markets Analyst
With GME stock rebounding, is it time to jump back in? The long term future could be good, but short-term speculators won't wait.

7 Education Stocks to Watch As Campuses Reopen

By Tezcan Gecgil, InvestorPlace Contributor
As more schools start to open back up, the education stocks that have stable revenue and high cash flows could stand to do well.

AMC Is a Wait-And-See Play as Streaming Services Dominate

By Lou Carlozo, InvestorPlace Contributor
Going to movies is a communal event. Your small screen or home theater cannot substitute for it, no matter how many subwoofers you install. But where AMC stock is concerned, I don't see things getting better – especially when I question what bona fide fuel went into its recent surge. 

Canoo Might Be Too Revolutionary

By Larry Ramer, InvestorPlace Contributor
Two of Canoo's innovations may turn off a high number of consumers, making GOEV stock much too risky at its current levels.

Zomedica Stock Volatility Continues as Truforma Launch Nears

By Louis Navellier and the InvestorPlace Research Staff
As Zomedica prepares to launch Truforma, its first commercial product, ZOM stock continues to experience volatility.

Nokia Has Become a Communist Utopia

By Josh Enomoto, InvestorPlace Contributor
The biggest irony with NOK stock is that the social media-driven push to save it may only be exacerbating its struggles.

Unfavorable Earnings Profile Doesn’t Bode Well for Iterum Therapeutics Stock

By David Moadel, InvestorPlace Contributor
It's encouraging that Iterum's oral antibiotic has blockbuster status potential, but the basic earnings data on ITRM stock signal caution.

Ranking the Top 7 Marijuana Stocks From Best to Worst

By Ian Bezek, InvestorPlace Contributor
Marijuana stocks are volatile right now. Cut through the noise with this ranking of seven leaders from best to worst.

It’s Not Just the Allegations That Hurt Clover Health

By Josh Enomoto, InvestorPlace Contributor
Clover Health is under fire from short seller Hindenburg Research, sending CLOV stock careening toward the ground. But that’s not the only factor to consider regarding the embattled organization.

Zomedica Continues to Fly High With Its Recent Positive Developments

By Muslim Farooque, InvestorPlace Contributor
ZOM stock has been on a tear this year, and is nearing the buy zone with the impending release of its Truforma Platform

Based on Bill Ackman’s Tweets, Pershing Square Tontine Could Be Ready to Move

By David Moadel, InvestorPlace Contributor
Bill Ackman is known for making deals and promoting businesses. His flair as a pitchman might be enough to send the PSTH stock price higher.

Nikola Requires More Progress and More Credibility Before It’s a Buy

By InvestorPlace Research Staff
NKLA stock is off sharply from its highs, but that doesn't make it cheap. With Nikola flailing, EV investors still can do better.
Load More Articles